Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 Infection

Multisystem inflammatory syndrome (MIS-C): a systematic review and meta-analysis of clinical characteristics, treatment, and outcomes

“…Other less frequent comorbidities were associated with cardiac, renal, neurological, dermatological, and hematological disorders. 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 ,…”

Clinical profile and outcomes of multisystem inflammatory syndrome in children (MIS‐C): Hospital‐based prospective observational study from a tertiary care hospital in South India

“…We compared the baseline, clinical characteristics, cardiac and investigative parameters of our study with previously published studies from India (Table 4). [11][12][13][14][15][16][17][18] The mean age among these studies ranged from 60 to 90 months with GI symptoms as the predominant presenting manifestation. Details of these studies, including presence of shock, requirement of inotrope infusion, mechanical ventilation, ICU requirement, presence of CAA and LV systolic function and SARS CoV-2 positivity among the patients, have been summarised.…”

Multisystem inflammatory syndrome in children (MIS-C) showing disseminated aspergillosis, cytomegalovirus reactivation and persistent SARS-COV-2: Case report with autopsy review

“…For the small number of patients who do not survive, in most studies, the causes of death are either not provided [3] , [5] , [6] , [10] or based on clinical impressions [11] . Given the relative novelty of MIS-C, post mortem examination can provide valuable information about this incompletely understood condition.…”

“…With treatment, the majority of patients survive [3] , [4] , [6] , [9] . Depending on the study, the mortality rate is low, in the range of 1.5–2.2 %, but rates of 15–25 % has been reported by some [2] , [10] , [11] . Most of the larger studies have not reported the causes of death.…”

“…Attention was initially drawn to that fact that MIS-C was not seen in Asian countries [3] , [5] . This has proven to be incorrect, as there are now reports, albeit very few, documenting MIS-C in patients in Asia, including Japan, South Korea, Indonesia, VietNam and India [10] , [11] , [20] , [21] , [22] , [23] .…”